No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Ombitasvir/Paritaprevir/r + Dasabuvir
Quality of Evidence: Low
Coadministration of emtricitabine/tenofovir-DF (200/300 mg once daily) and ombitasvir/paritaprevir/ritonavir + dasabuvir increased emtricitabine AUC, Cmax and Cmin by 5%, 7% and 9%, respectively and tenofovir Cmax, AUC and Cmin by 7%, 13% and 24%, respectively. Ombitasvir Cmax, AUC and Cmin decreased by 11%, 1% and 3%, respectively. Paritaprevir Cmax and AUC decreased by 32% and 16%, but Cmin increased by 6%. Dasabuvir Cmax, AUC and Cmin all decreased by 15%. Emtricitabine/tenofovir-DF can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required.